Scalp Metastasis After Breast Cancer Surgery: A Case Report
Jingxuan Wu,Wenzhu Zhang,Hong Zhang,Xingjia Lu,Biqing Luan,Qizhi Yang,Liang Chen,Wenlin Chen,Fei Ge
DOI: https://doi.org/10.2147/ott.s456532
IF: 4
2024-05-27
OncoTargets and Therapy
Abstract:Jingxuan Wu, 1, 2 Wenzhu Zhang, 1, 2 Hong Zhang, 1, 2 Xingjia Lu, 1, 2 Biqing Luan, 1, 2 Qizhi Yang, 1, 2 Liang Chen, 1 Wenlin Chen, 3 Fei Ge 1 1 Department of Breast Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, 650000, People's Republic of China; 2 No. 1 School of Clinical Medicine, Kunming Medical University, Kunming, 650000, People's Republic of China; 3 Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650000, People's Republic of China Correspondence: Fei Ge, Department of Breast Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, 650000, People's Republic of China, Email Wenlin Chen, Third Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650000, People's Republic of China, Email Breast cancer is one of the most common malignant tumors affecting women worldwide. Breast cancer is a complex disease characterized by abnormal growth of cells in the breast tissue. Metastasis, the spread of cancer cells from the primary tumor site to distant organs, is a major challenge in the management of breast cancer. Although metastasis to distant sites is a well-known feature of breast cancer, scalp involvement is relatively rare. The occurrence of scalp metastasis signifies an advanced stage of the disease. The 51-year-old female discovered a firm, painless mass in her right breast that had been there for two years. It had been pricking for a month, and the biopsy revealed that the mass was invasive carcinoma of the right breast. Imaging tests suggested that the tumor was malignant. Adjuvant endocrine therapy and postoperative adjuvant chemotherapy were administered following a modified radical resection for breast cancer. Eleven months later, radiation treatment and replace endocrine therapy was used. 32 months following surgery, a scalp tumor was discovered; a pathology biopsy verified the origin of the breast cancer; three months later, bone, brain, and visceral metastases were discovered. After that, she received oral capecitabine treatment and was admitted into the hospital for advanced rescue treatment. She is currently in the disease stability state, her disease is effectively managed, and no new metastatic lesions have been discovered. Keywords: breast cancer, scalp metastasis, chemotherapy, radiotherapy, endocrine therapy, case report There was a 51-year-old woman received treatment in the First Affiliated Hospital of Kunming Medical University because of a hard lump at her right breast, which has found for two years and felt it tingling for a month. After a medical examination we found that there was no change in the breast skin, the lump was hard, painless and boundaryless. In addition, the diameter was 3 cm. She used to have hypertension level 2 and undergone surgery of breast fibroadenoma and CINI. She took nifedipine orally every day so that her blood pressure was well controlled. The mammography suggested the lump was malignant tumor (Figure 1). The MRI also suggested a malignant tumor (Figure 2). After core needle biopsy the histopathological examination indicated a invasive ductal carcinoma and the estrogen receptor was 80% positive, the progesterone receptor was 3% positive, Her-2 was negative, and KI-67 was 10% positive (Figure 3). It was confirmed as type Luminal B breast cancer. We performed radical mastectomy and axillary sentinel lymph nodes biopsy, while the result of intraoperative freezing suggested no cancer metastasis in the axillary sentinel lymph nodes (Figure 4); at the same time, we found a malignant tumor on the part of the surface of the pectoralis major muscle intraoperatively, and a few of hard swollen axillary lymph nodes. Eventually, we removed the grade I and II axillary lymph nodes and part of the tumor-infiltrated pectoral major muscle. Postoperative pathological suggested: The tumor size was 2.6×2.2×2.0cm. It is an invasive ductal carcinoma, grade WHO II, the estrogen receptor was 90% positive, the progesterone receptor was 90% positive, Her-2 was negative, and KI-67 was 40% positive (Figure 5). It is confirmed as type Luminal B breast cancer, the same as before surgery. Its peripheral margin, skin, nipple, and basal margin were all negative, and no nerves or vas were violated, and simultaneously there was no cancer cell found in the resected axillary lymph nodes. After one month recovery, she started adjuvant chemotherapy (docetaxel combined with cyclophosphamide four-cycle). Thereafter she started endocrine therapy (oral tamoxifen) for eight months, in the meantime she conducts regular reviews. She found erythema on the right chest wall -Abstract Truncated-
oncology,biotechnology & applied microbiology